厄洛替尼治疗化疗失败晚期非小细胞肺癌的临床观察

目的探讨厄洛替尼2线或3线治疗化疗失败晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法收集2008年3月至2010年6月化疗失败的ⅢB／Ⅳ期NSCLC患者45例，口服厄洛替尼150mg／次，每日1次，直至疾病进展，观察其，临床疗效及不良反应，并进行随访，应用Kaplan—Meier方法进行生存分析。结果45例患者随访截止日期为2010年9月30日。厄洛替尼治疗总有效率为42％，疾病控制率为77．8％，中位无进展生存时间为8个月，中位总生存时间为15个月。主要不良反应为1～2度的皮疹和腹泻。结论厄洛替尼是治疗化疗失败晚期NSCLC患者的有效药物，对于我国表皮生长因子（EGFR）状态不明的患者仍然能够达到很好的疗效，并且无严重不良反应。

Clinical study on the efficacy and safety of erlotinib in treatment of advanced non - small cell lung cancer with failed prior chemotherapy

Objective To investigate the efficacy and adverse reaction of erlotinib in 2nd and 3rd treatment of advanced non - small cell lung cancer （ NSCLC ） patients with failed prior chemotherapy. Methods Patients with advanced NSCLC（ⅢB/Ⅳ stage） , who failed to prior chemotherapy, were recruited in this study,from March 2008 to June 2010. Erlotinib was given orally to the patients at 150 rag/d, once daily until disease progression. The clinical outcome and adverse reaction were observed. Patients were followed up. Kaplan - Meier method was used to perform survival analysis. Resuits Forty - five NSCLC patients were enrolled into the study and followed up until September 30, 2010. 42% patients with complete response and partial response. Disease control rate was 77.8%. Median time to progression and median overall survival period were 8 and 15 months, respectively. The main adverse reactions are Ⅰ to Ⅱgrade skin rashes and diarrhea. Conclusions Erlotinib is an effective agent in treatment of advanced NSCLC patients after failure of chemotherapy. It is also effective in treating the patients of our country with unkown EGFR mutation status, and the tolerance is well.